Robotic Waterjet Resection for Men With Prostate Cancer Suffering From Lower Urinary Tract Symptoms

To evaluate the impact of Aquablation on circulating tumor cells (CTCs) in men with localized prostate cancer. This prospective study included subjects with biopsy-positive mpMRI visible lesions (PIRADS ≥3) who underwent Aquablation. Ten mL blood samples were collected before, during and after the p...

Full description

Saved in:
Bibliographic Details
Published inUrology (Ridgewood, N.J.) Vol. 198; pp. 153 - 157
Main Authors Teoh, Jeremy Yuen Chun, Yuen, Steffi Kar Kei, Lau, Becky Sui Yan, Lai, Franco Pui Tak, Lee, Ka Lok, Chiu, Peter Ka Fung, Yee, Chi Hang, Ng, Chi Fai
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2025
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To evaluate the impact of Aquablation on circulating tumor cells (CTCs) in men with localized prostate cancer. This prospective study included subjects with biopsy-positive mpMRI visible lesions (PIRADS ≥3) who underwent Aquablation. Ten mL blood samples were collected before, during and after the procedure to measure CTC counts using an immunofluorescence assay. The mean age of participants was 63.4 years, with a baseline PSA of 8.9 ng/mL and a prostate volume of 60.3 mL. All subjects experienced reduced IPSS scores and stable or improved SHIM and MSHQ-EjD scores. Detectable CTCs were found in 80% of subjects before Aquablation, 100% immediately after Aquablation, 20% on post-op day 2, and 60% on post-op day 7. The mean number of CTCs per patient 10 mL blood draw was 1.2 preoperatively, 3.2 immediately post-op, 0.2 on day 2, and 1.0 on day 7. Prostate volumes decreased significantly at 3 and 6 months, with corresponding reductions in PSA levels. There were no adverse events reported. Specifically, no instances of incontinence, erectile dysfunction, ejaculatory dysfunction, or rectal toxicity were observed. At 6-month follow-up, all baseline mpMRI lesions were no longer visible on mpMRI and follow-up biopsies showed no grade group progression. In an active surveillance population, Aquablation resulted in improved urinary function, stable or improved sexual function, and a transient spike in CTCs lasting <2 days that did not result in any oncologic concern. Aquablation may be considered a safe option for men with localized prostate cancer who require treatment for LUTS due to BPH.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0090-4295
1527-9995
1527-9995
DOI:10.1016/j.urology.2025.01.020